Intra-articular Injections of Allogeneic Platelet-Rich Plasma from Responder Patients for the Treatment of Knee Osteoarthritis: A Pilot and Feasibility Clinical Trial.
Mikel Sánchez, Jorge Guadilla, Cristina Jorquera et al.
✦ AI-curated · Sources linked
In 30 seconds
This pilot feasibility clinical trial evaluated intra-articular allogeneic platelet-rich plasma (PRP) from responder donors in patients with knee osteoarthritis who had not responded to autologous PRP. Sixteen patients enrolled and 14 completed follow-up. KOOS pain and visual analogue scale scores improved significantly from baseline to 12 months, while the Lequesne Index improved through 6 months (P < .005). Six patients (42.9%) achieved a Minimal Clinically Important Improvement, and no adverse reactions were reported. The findings suggest potential benefit and feasibility, but the authors call for further research.
Key findings
- KOOS pain and visual analogue scale scores improved significantly from baseline to 12 months; the Lequesne Index improved through 6 months (P < .005).
- Six patients (42.9%) achieved a Minimal Clinically Important Improvement.
- No adverse reactions to allogeneic PRP were reported.
Why it matters
Patients who do not benefit from autologous PRP may have limited options within this treatment approach. These preliminary findings indicate that donor PRP was feasible and was not associated with reported adverse reactions in this trial, alongside improvements in several symptom measures. The small pilot study supports further evaluation rather than establishing effectiveness or safety for broader use.
What to keep in mind
This was a pilot feasibility trial with 16 enrolled patients and 14 completing follow-up; the abstract reports no comparator group.